Which patients with systemic lupus erythematosus are eligible for add-on treatment with intravenous belimumab (Benlysta)?

Intravenous belimumab (Benlysta) is indicated as add-on therapy for patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus and high disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.